Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Stock Performance

Shares of NASDAQ CLLS opened at $1.91 on Wednesday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $2.25. Cellectis has a 52-week low of $1.70 and a 52-week high of $3.77. The stock has a market capitalization of $106.17 million, a P/E ratio of -1.47 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period last year, the business posted ($0.31) EPS. As a group, sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. First Affirmative Financial Network bought a new position in Cellectis in the 3rd quarter valued at about $45,000. XTX Topco Ltd bought a new position in Cellectis in the 2nd quarter valued at about $29,000. Finally, Principal Financial Group Inc. increased its stake in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.